Midway Pharmaceuticals Inc.
This article was originally published in Start Up
Midway Pharmaceuticals Inc. has a non-antibiotic approach to the raging problem of hospital-acquired infections. Its Polymer BioShield is a high molecular weight polyethylene glycol that when ingested has a multifactorial effect in the gut. It acts as an artificial barrier in situations where a patient's own mucousal barrier has been compromised. Perhaps more importantly, it appears to affect bacterial signaling, preventing pathogens from ganging up and launching an attack.
You may also be interested in...
Polymers have long been useful as critical components in delivering or stabilizing a variety of medicines. Now a small band of companies that includes Genzyme, Ilypsa and Midway Pharmaceuticals is going one step further: they are designing polymers that aren't just inert drug delivery vehicles, but are themselves therapeutic agents.
Despite Big Pharma's struggles, the availability of compounds developed for other pain indications could energize start-ups' interest in irritable bowel syndrome.
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)